What is a stock summary page? Click here for an overview.
Business Description
CASI Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US14757U1097
Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.73 | |||||
| Equity-to-Asset | 0.03 | |||||
| Debt-to-Equity | 11.96 | |||||
| Debt-to-EBITDA | -0.6 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -19.62 | |||||
| Beneish M-Score | -5.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.7 | |||||
| 3-Year EBITDA Growth Rate | 2.5 | |||||
| 3-Year EPS without NRI Growth Rate | -0.8 | |||||
| 3-Year FCF Growth Rate | 14.8 | |||||
| 3-Year Book Growth Rate | -73 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 60.76 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.02 | |||||
| 9-Day RSI | 48.51 | |||||
| 14-Day RSI | 45.94 | |||||
| 3-1 Month Momentum % | -20.3 | |||||
| 6-1 Month Momentum % | -63.64 | |||||
| 12-1 Month Momentum % | -13.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | |||||
| Quick Ratio | 0.94 | |||||
| Cash Ratio | 0.44 | |||||
| Days Inventory | 269.01 | |||||
| Days Sales Outstanding | 121.89 | |||||
| Days Payable | 43.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | -42.73 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.06 | |||||
| Operating Margin % | -137.41 | |||||
| Net Margin % | -137.57 | |||||
| FCF Margin % | -103.25 | |||||
| ROE % | -305.03 | |||||
| ROA % | -65.03 | |||||
| ROIC % | -127.27 | |||||
| 3-Year ROIIC % | 9.53 | |||||
| ROC (Joel Greenblatt) % | -162.65 | |||||
| ROCE % | -86.19 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.15 | |||||
| PB Ratio | 16.93 | |||||
| Price-to-Tangible-Book | 20.15 | |||||
| EV-to-EBIT | -1 | |||||
| EV-to-EBITDA | -1 | |||||
| EV-to-Revenue | 1.31 | |||||
| EV-to-Forward-Revenue | 1.98 | |||||
| EV-to-FCF | -1.26 | |||||
| Price-to-GF-Value | 0.82 | |||||
| Earnings Yield (Greenblatt) % | -100 | |||||
| FCF Yield % | -94.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CASI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CASI Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 28.537 | ||
| EPS (TTM) ($) | -2.57 | ||
| Beta | 1.23 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 107.22 | ||
| 14-Day RSI | 45.94 | ||
| 14-Day ATR ($) | 0.191381 | ||
| 20-Day SMA ($) | 2.04119 | ||
| 12-1 Month Momentum % | -13.11 | ||
| 52-Week Range ($) | 1.88 - 7.67 | ||
| Shares Outstanding (Mil) | 15.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CASI Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CASI Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CASI Pharmaceuticals Inc Frequently Asked Questions
What is CASI Pharmaceuticals Inc(CASI)'s stock price today?
The current price of CASI is $2.02. The 52 week high of CASI is $7.67 and 52 week low is $1.88.
When is next earnings date of CASI Pharmaceuticals Inc(CASI)?
The next earnings date of CASI Pharmaceuticals Inc(CASI) is 2025-05-20 Est..
Does CASI Pharmaceuticals Inc(CASI) pay dividends? If so, how much?
CASI Pharmaceuticals Inc(CASI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers